Methodologies used to identify and characterize interactions among antiepileptic drugs

References

• Johannessen Landmark C, Rytter E, Johannessen SI. Clinical use of antiepileptic drugs at a referral center for epilepsy. Seizure16, 356–364 (2007).
   PubMedGoogle Scholar
• Johannessen Landmark C, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of patients with epilepsy in a nation-wide population. Epilepsy Res.95, 51–59 (2011).
   PubMedGoogle Scholar
• Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol. Scand.113, 405–411 (2006); erratum in: Acta Neurol. Scand.114, 70 (2006).
   PubMed Web of Science ®Google Scholar
• Johnell K, Fastbom J. Antiepileptic drug use in community-dwelling and institutionalized elderly: a nation-wide study of over 1,300,000 older people. Eur. J. Clin. Pharmacol.67(10), 1069–1075 (2011).
   PubMed Web of Science ®Google Scholar
• Halvorsen KH, Granas AG, Engeland A, Ruthe S. Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs. Pharmacoepidemiol. Drug Saf. doi:10.1002/pds.2232 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Brodie MJ, Sills GJ. Combining antiepileptic drugs – rational polytherapy? Seizure20(5), 369–375 (2011).
   PubMed Web of Science ®Google Scholar
• Deckers CL, Czuczwar SJ, Hekster YA et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia41, 1364–1374 (2000).
   PubMed Web of Science ®Google Scholar
• Jonker DM, Voskuyl RA, Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia48, 412–434 (2007).
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia50, 387–397 (2009).
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Andres-Mach MM, Ratnaraj N, Patsalos PN, Czuczwar SJ. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia48, 806–815 (2007).
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Andres MM, Czuczwar P et al. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia47, 10–20 (2006).
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur. J. Pharmacol.595, 13–21 (2008).
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ. Isobolographic characterizations of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse electroshock-induced seizure model. Naunyn Schmiedebergs Pharmacol.379(2), 163–179 (2009).
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Filip D, Florek-Luszcki M. Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis. Epilepsy Res.98(2–3), 148–156 (2012).
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Kaplanski J, Swiderska-Dziewit G, Gergont A, Kroczka S, Kacinski M. Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin. Drug Metab. Toxicol.5, 131–136 (2009).
   PubMed Web of Science ®Google Scholar
• Luszcki JJ, Trojanr MK, Ratanaraj N, Patsalos PN, Czuczwar SJ. Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model. Epilepsy Res.90(3), 188–198 (2010).
   PubMedGoogle Scholar
• Rowan AJ, Meijer JW, de Beer-Pawlikowski N, van der Geest P, Meinardi H. Valproate–ethosuximide combination therapy for refractory absence seizures. Arch. Neurol.40(13), 797–802 (1983).
   PubMedGoogle Scholar
• Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate–lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia40, 1141–1146 (1999).
   PubMed Web of Science ®Google Scholar
• Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet342, 185–186 (1993).
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol.61, 246–255 (2006).
   PubMed Web of Science ®Google Scholar
• Besag FM, Berry DJ, Pool F, Boyd SG, Berry D, Neville BG. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia39(2), 183–187 (1998).
   PubMed Web of Science ®Google Scholar
• Sake JK, Hebert D, Isojarvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs24, 1055–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol.2, 347–356 (2003).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol.2, 473–481 (2003).
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev. Neurother.10(1), 119–140 (2010).
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol. Ther.106(1), 97–132 (2005).
   PubMed Web of Science ®Google Scholar
• Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics6(1), 16–21 (2006).
   Google Scholar
• Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit.29, 687–710 (2007).
   PubMed Web of Science ®Google Scholar
• Seo T, Nagata R, Ishitsu T et al. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics9(5), 527–537 (2008).
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther. Drug Monit.24(3), 332–337 (2002).
   PubMedGoogle Scholar
• Giraud C, Tran A, Rey E, Vincent J, Trèluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab. Dispos.32(11), 1279–1286 (2004).
   PubMed Web of Science ®Google Scholar
• Park PW, Seo YH, Ahn JY, Kim KA, Park JYJ. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. Clin. Pharm. Ther.34(5), 569–574 (2009).
   Google Scholar
• Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res.95(1–2), 1–8 (2011).
   PubMed Web of Science ®Google Scholar
• Blanca Sánchez M, Herranz JL, Leno C et al. UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther. Drug Monit.32(2), 177–184 (2010).
   PubMed Web of Science ®Google Scholar
• Chung JY, Cho JY, Yu KS et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther.83(4), 595–600 (2008).
   PubMed Web of Science ®Google Scholar
• Rivers F, O’Brien TJ, Callaghan R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. Eur. J. Pharmacol.598, 1–8 (2008).
   PubMed Web of Science ®Google Scholar
• Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia47, 1253–1284 (2006).
   PubMed Web of Science ®Google Scholar
• Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D’Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia48(Suppl. 5), 140–149 (2007); erratum in: Epilepsia48, 2380 (2007).
   PubMed Web of Science ®Google Scholar
• Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology55, 1364–1375 (2008).
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Collart P, Gerin B et al.In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos.27(2), 250–254 (1999).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Ghattaura S, Ratnaraj N, Sander JW. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia47, 1818–1821 (2006).
   PubMedGoogle Scholar
• Nakasa H, Nakamura H, Ono S et al. Prediction of drug–drug interactions of zonisamide metabolism in humans from in vitro data. Eur. J. Clin. Pharmacol.54, 177–183 (1998).
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Sachdeo SK, Levy R et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia43(7), 691–696 (2002).
   PubMed Web of Science ®Google Scholar
• Li AP, Maural P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. Preclinical evaluation of drug–drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interactions107, 5–16 (1997).
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J. Pharmacokinet. Biopharm.24, 475–490 (1996).
   PubMedGoogle Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann. Reb. Pharmacol. Toxicol.38, 389–430 (1998).
   PubMed Web of Science ®Google Scholar
• Brown HS, Ito K, Galetin A, Houston JB. Predictions of in vivo drug–drug interactions from in vitro data: impact of incorporating parallell pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol.60(5), 508–518 (2005).
   PubMed Web of Science ®Google Scholar
• Brown HS, Galetin A, Halifax D, Houston JB. Predictions of in vivo drug–drug interactions from in vitro data: factors affecting prototypic drug–drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin. Pharmacokinet.45(10), 1035–1050 (2006).
   PubMed Web of Science ®Google Scholar
• Youdim KA, Zayed A, Dickins M et al. Application of CYP3A4 in vitro data to predict clinical drug–drug interactions; predictions of compounds as object of interaction. Br. J. Clin. Pharmacol.65, 680–692 (2008).
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Tucker J, Trigg S, Riley RI. Prediction of CYP2C9-mediated drug–drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab. Dispos.33(11), 1700–1707 (2005).
   PubMed Web of Science ®Google Scholar
• Brown HS, Wilby AJ, Alder J, Houston JB. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay. Drug Metab. Dispos.38(12), 2139–2146 (2010).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Alavijeh MS, Semba J et al. A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine. J. Pharmacol. Methods28, 21–28 (1992).
   Google Scholar
• Walker MC, Tong X, Perry H et al. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br. J. Pharmacol.130, 242–248 (2000).
   PubMed Web of Science ®Google Scholar
• Hachad H, Ragueneau-Majlessi I, Levy RH. A useful tool for drug interactions evaluation: the University of Washington metabolism and transport drug interactions database. Hum. Genomics5(1), 61–72 (2010).
   PubMedGoogle Scholar
• Nunes T, Sicard E, Almeida L et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr. Med. Res. Opin.26(6), 1335–1362 (2010).
   Google Scholar
• Almeida L, Nunes T, Sicard E et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol. Scand.121(4), 257–264 (2010).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Wilson EA, Wesche DL et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine and vaproate is patients with partial epilepsy. Epilepsia46(9), 1407–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Sabers A, Buchholt JM, Uldall P et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res.47, 151–154 (2001).
   PubMed Web of Science ®Google Scholar
• Sabers A, Öhman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology61, 570–571 (2003).
   PubMed Web of Science ®Google Scholar
• Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progesterone, reduces lamotrigine serum concentrations. Epilepsia46(9), 1414–1417 (2005).
   PubMed Web of Science ®Google Scholar
• Neef C, de Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin. Pharmacol. Ther.43, 372–375 (1988).
   PubMed Web of Science ®Google Scholar
• Parmeggiani A, Riva R, Posar A, Rossi PG. Possible interaction between acyclovir and antiepileptic treatment. Ther. Drug Monit.17, 312–315 (1995).
   PubMed Web of Science ®Google Scholar
• Perucca E, Gidal BE, Baltès E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res.53(1–2), 47–56 (2003).
   PubMed Web of Science ®Google Scholar
• Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration–response relationships in patients with epilepsy. Epilepsia49, 1123–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Rosenfeld WE, Vazquez B et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia50, 1899–1909 (2009).
   PubMed Web of Science ®Google Scholar
• Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia50(5), 1150–1157 (2009).
   PubMed Web of Science ®Google Scholar
• Halász P, Kälviäinen R, Mazurkiewicz-Beldzinska M et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia50, 443–453 (2009).
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Battino D, Berry DJ et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit.25(3), 347–363 (2003).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia49, 1239–1276 (2008).
   PubMed Web of Science ®Google Scholar
• Brandt C, May TW. Therapeutic drug monitoring of newer antiepileptic drugs. J. Lab. Med.35(3), 161–169 (2011).
   Google Scholar
• Reimers A. Trends and changes in the clinical use of lamotrigine. Pharmacoepidemiol. Drug Saf.128, 132–139 (2009).
   Google Scholar
• May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther. Drug Monit.24, 366–374 (2002).
   PubMed Web of Science ®Google Scholar
• May TW, Rambeck B, Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and comedication. Ther. Drug Monit.25, 690–699 (2003).
   PubMed Web of Science ®Google Scholar
• May TW, Rambeck B, Neb R et al. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther. Drug Monit.29, 789–794 (2007).
   PubMed Web of Science ®Google Scholar
• May TW, Boor R, Rambeck B et al. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. Ther. Drug Monit.33, 214–221 (2011).
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders: a population-based study of prescriptions. Epilepsy Res.87, 31–39 (2009).
   PubMed Web of Science ®Google Scholar
• van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT. Antiepileptic drug utilization in children from 1997–2005 – a study from The Netherlands. Eur. J. Clin. Pharmacol.64, 1013–1020 (2008).
   PubMedGoogle Scholar
• Ackers R, Besag FM, Wade A, Murray ML, Wong IC. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Arch. Dis. Child.94(6), 443–447 (2009).
   PubMedGoogle Scholar
• Hsia Y, Neubert A, Sturkenboom M et al. Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia51(5), 789–796 (2010).
   PubMedGoogle Scholar
• Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch. Neurol.62(9), 1432–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Arif H, Svoronos A, Resor SR Jr, Buchsbaum R, Hirsch LJ. The effect of age and comedication on lamotrigine clearance, tolerability and efficacy. Epilepsia52(10), 1905–1913 (2011).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Bourgeois BFD. The Epilepsy Prescriber’s Guide to Antiepileptic Drugs. Cambridge University Press, Cambridge, UK (2010).
   Google Scholar
• Sargentini-Maier ML, Espie P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab. Disposit.36, 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res.92(2–3), 89–124 (2010).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res.43(1), 11–58 (2001).
   PubMed Web of Science ®Google Scholar